Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|NSCLC|Triple-negative Breast Cancer|CRC
Interventions: BIOLOGICAL: OMO-103
Sponsor: Peptomyc S.L.